SRZN - Surrozen, Inc./DE

28.14
-2.495   -8.866%

Share volume: 111,009
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$30.64
-2.50
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 43%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-12.74%
1 Month
7.65%
3 Months
38.48%
6 Months
102.01%
1 Year
180.60%
2 Year
226.83%
Key data
Stock price
$28.14
P/E Ratio 
N/A
DAY RANGE
$28.00 - $31.57
EPS 
-$48.27
52 WEEK RANGE
$5.90 - $33.96
52 WEEK CHANGE
$171.01
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
11.487 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$151,264
AVERAGE 30 VOLUME 
$128,419
Company detail
CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Recent news